Associated Genetic Biomarkers
DNAJB1 is altered in 0.36% of all cancers with fibrolamellar carcinoma, high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, and hepatocellular carcinoma having the greatest prevalence of alterations .
The most common alterations in DNAJB1 are DNAJB1 Amplification (0.12%) and DNAJB1 Loss (0.02%) .
DNAJB1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains DNAJB1 status as an inclusion criterion, 1 is phase 1 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is DNAJB1-PRKACA Fusion .
Significance of DNAJB1 in Diseases
Fibrolamellar Carcinoma +
DNAJB1 is altered in 78.26% of fibrolamellar carcinoma patients .
DNAJB1 is an inclusion criterion in 1 clinical trial for fibrolamellar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DNAJB1 status and fibrolamellar carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.